Steady progress. I listened to the webinar this morning, the revenue from last quarter doesn't include the $1.6M from Viatris. That will be invoiced this current quarter.
There could be more deals from Viatris as they are always bidding on public health tenders.
Atomo have been dangling development deals with large multinationals for a while now. I hope we can see some of those come to fruition.
Looks like FebriDx demand in the US is light so far, probably won't move the needle until LDX secures CLIA waiver.
Steady progress. I listened to the webinar this morning, the...
Add AT1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.8¢ |
Change
0.001(3.70%) |
Mkt cap ! $17.25M | |||
| Open | High | Low | Value | Volume |
| 2.8¢ | 2.8¢ | 2.8¢ | $504 | 18K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 971548 | 2.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.9¢ | 579431 | 3 |
View Market Depth
| Last trade - 10.01am 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
2.9¢ |
Change
0.001 ( 7.41 %) |
||||
| Open | High | Low | Volume | ||
| 2.7¢ | 2.9¢ | 2.7¢ | 45523 | ||
| Last updated 10.56am 07/06/2024 ? | |||||
| AT1 (ASX) Chart |